Contact
searchSearch
HMP Global
Login

Lung Cancer Resource Center

News
Real-World Treatment Pathways in Extensive-Stage SCLC Show Significant Gaps in Care
11/24/2025
Juliet Gallagher
A retrospective analysis of a nationwide US electronic health record (EHR)-derived database revealed poor outcomes and significant treatment variability among patients with extensive-stage small cell lung cancer (ES-SCLC) following first-line...
A retrospective analysis of a nationwide US electronic health record (EHR)-derived database revealed poor outcomes and significant treatment variability among patients with extensive-stage small cell lung cancer (ES-SCLC) following first-line...
A retrospective analysis of a...
11/24/2025
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
News
Regional Disparities Persist Despite National Declines in Lung Cancer Mortality Rates
11/18/2025
Lisa Kuhns, PhD, MD
Lung cancer mortality has fallen substantially across the United States since 1999, but deep regional, gender, racial, and state-level disparities persist despite overall progress, according to a study published in Respiratory Research.
Lung cancer mortality has fallen substantially across the United States since 1999, but deep regional, gender, racial, and state-level disparities persist despite overall progress, according to a study published in Respiratory Research.
Lung cancer mortality has fallen...
11/18/2025
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
Research Reports
Enhancing Multidisciplinary Team Processes in Lung Cancer Care: A Self-Assessment Toolkit and Best Practices
02/09/2024
Adrien Moucquot; Poka Cui; Heather Moses; David Dellamonica; Peter Blanshard; María Teresa Campos-Partera
Poka Cui and colleagues completed a literature review along with interviews involving lung cancer multidisciplinary teams from 24 medical centers across Europe and Canada. In this report, they also introduce a comprehensive self-assessment...
Poka Cui and colleagues completed a literature review along with interviews involving lung cancer multidisciplinary teams from 24 medical centers across Europe and Canada. In this report, they also introduce a comprehensive self-assessment...
Poka Cui and colleagues...
02/09/2024
Journal of Clinical Pathways
News
Score Model for Prediction and Prognosis of Patients With Advanced NSCLC Treated With Nivolumab or Pembrolizumab
09/27/2022
Yvette C. Terrie, BS Pharm, RPh
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide...
09/27/2022
Journal of Clinical Pathways
News
Evaluating Multidisciplinary Care Among Patients With Lung Cancer Treated in a Community-Based Health Care System
06/23/2022
Ellen Kurek
Researchers established a multidisciplinary lung cancer clinic in a large, community-based healthcare system and conducted a prospective, comparative-effectiveness study to evaluate patients’ experiences with and outcomes of clinic care.
Researchers established a multidisciplinary lung cancer clinic in a large, community-based healthcare system and conducted a prospective, comparative-effectiveness study to evaluate patients’ experiences with and outcomes of clinic care.
Researchers established a...
06/23/2022
Journal of Clinical Pathways
News
Artificial Intelligence-Powered Spatial Analysis of TILs Predicts Treatment Outcomes With ICIs in NSCLC
05/16/2022
Ellen Kurek
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a...
05/16/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Tumor Genomic Profiling to Among Patients With Metastatic Lung Adenocarcinoma
05/11/2022
Ellen Kurek
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor...
05/11/2022
Journal of Clinical Pathways
News
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among US Patients With Early-Stage NSCLC
04/05/2022
Marta Rybczynski
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a...
04/05/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Adjuvant Osimertinib for Resected EGFR-Mutant NSCLC
04/01/2022
Janelle Bradley
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a...
04/01/2022
Journal of Clinical Pathways

Expert Insights

Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part I
05/21/2026
Mark A. Socinski, MD
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this...
05/21/2026
Journal of Clinical Pathways
Olivia Lynch
Interview
Where Access Breaks Down: Uncovering Persistent Disparities in Early-Stage Lung Cancer Treatment
04/21/2026
Olivia Lynch, MD, MPH
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research...
04/21/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
JJN
Interview
NSCLC Clinical Pathways in the Era of Molecular Complexity, AI, and Value-Based Care
02/20/2026
Jorge J. Nieva, MD
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest...
02/20/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways

Newsfeed

News
Real-World Treatment Pathways in Extensive-Stage SCLC Show Significant Gaps in Care
11/24/2025
Juliet Gallagher
A retrospective analysis of a nationwide US electronic health record (EHR)-derived database revealed poor outcomes and significant treatment variability among patients with extensive-stage small cell lung cancer (ES-SCLC) following first-line...
A retrospective analysis of a nationwide US electronic health record (EHR)-derived database revealed poor outcomes and significant treatment variability among patients with extensive-stage small cell lung cancer (ES-SCLC) following first-line...
A retrospective analysis of a...
11/24/2025
Journal of Clinical Pathways
News
Regional Disparities Persist Despite National Declines in Lung Cancer Mortality Rates
11/18/2025
Lisa Kuhns, PhD, MD
Lung cancer mortality has fallen substantially across the United States since 1999, but deep regional, gender, racial, and state-level disparities persist despite overall progress, according to a study published in Respiratory Research.
Lung cancer mortality has fallen substantially across the United States since 1999, but deep regional, gender, racial, and state-level disparities persist despite overall progress, according to a study published in Respiratory Research.
Lung cancer mortality has fallen...
11/18/2025
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
Score Model for Prediction and Prognosis of Patients With Advanced NSCLC Treated With Nivolumab or Pembrolizumab
09/27/2022
Yvette C. Terrie, BS Pharm, RPh
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide...
09/27/2022
Journal of Clinical Pathways
News
Evaluating Multidisciplinary Care Among Patients With Lung Cancer Treated in a Community-Based Health Care System
06/23/2022
Ellen Kurek
Researchers established a multidisciplinary lung cancer clinic in a large, community-based healthcare system and conducted a prospective, comparative-effectiveness study to evaluate patients’ experiences with and outcomes of clinic care.
Researchers established a multidisciplinary lung cancer clinic in a large, community-based healthcare system and conducted a prospective, comparative-effectiveness study to evaluate patients’ experiences with and outcomes of clinic care.
Researchers established a...
06/23/2022
Journal of Clinical Pathways
News
Artificial Intelligence-Powered Spatial Analysis of TILs Predicts Treatment Outcomes With ICIs in NSCLC
05/16/2022
Ellen Kurek
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a...
05/16/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Tumor Genomic Profiling to Among Patients With Metastatic Lung Adenocarcinoma
05/11/2022
Ellen Kurek
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor...
05/11/2022
Journal of Clinical Pathways
News
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among US Patients With Early-Stage NSCLC
04/05/2022
Marta Rybczynski
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a...
04/05/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Adjuvant Osimertinib for Resected EGFR-Mutant NSCLC
04/01/2022
Janelle Bradley
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a...
04/01/2022
Journal of Clinical Pathways
News
Biomarker Testing Rates and Turnaround Times for Patients With NSCLC Receiving First-Line Therapy in The US Oncology Network
04/01/2022
Janelle Bradley
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90%...
04/01/2022
Journal of Clinical Pathways
News
Guideline-Based Pathways Could Streamline Prior Authorization Processes
05/21/2026
Rebecca Amrick
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have...
05/21/2026
Journal of Clinical Pathways
News
Higher Radon Levels Connected to Increased Risk of Ovarian Cancer in Postmenopausal Women
05/21/2026
Rebecca Amrick
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds...
05/21/2026
Journal of Clinical Pathways
News
Improving Geriatric Care for Older Patients With MM
05/20/2026
Rebecca Amrick
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have...
05/20/2026
Journal of Clinical Pathways
News
High-Risk Individuals Delay Lung Cancer Screenings Until Eligible Despite Expanded Medicare Access
05/18/2026
Rebecca Amrick
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s...
05/18/2026
Journal of Clinical Pathways
News
Dexamethasone Prophylaxis is a Promising Intervention Therapy for Patients With RRMM Receiving Cilta-Cel
05/15/2026
Rebecca Amrick
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows...
05/15/2026
Journal of Clinical Pathways
News
HCC Incidence Higher in Rural Populations Due to Changing Risk Factors and Access Barriers
05/15/2026
Rebecca Amrick
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC)...
05/15/2026
Journal of Clinical Pathways
News
A New Clinic in Minneapolis is Expected to Expand Health Care Access to Low-Income Populations
05/12/2026
Rebecca Amrick
A new clinic in Minnesota has recently opened to expand care access and treat low-income populations in Southside Minneapolis.
A new clinic in Minnesota has recently opened to expand care access and treat low-income populations in Southside Minneapolis.
A new clinic in Minnesota has...
05/12/2026
Journal of Clinical Pathways
News
Study Finds Comparable Outcomes for Regorafenib and FTD/TPI Sequencing in Metastatic Colorectal Cancer
05/12/2026
Rebecca Amrick
A real-world study suggests that the sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) may have minimal impact on survival outcomes in patients with metastatic colorectal cancer, underscoring the need for personalized treatment...
A real-world study suggests that the sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) may have minimal impact on survival outcomes in patients with metastatic colorectal cancer, underscoring the need for personalized treatment...
A real-world study suggests that...
05/12/2026
Journal of Clinical Pathways
News
Improved Diagnostic Timing Could Lead to Better Outcomes for Patients With Ovarian Cancer
05/11/2026
Rebecca Amrick
A study using nonlinear modeling shows how diagnostics for ovarian cancer (OC) are impacted by the wait time paradox and recommends improving diagnostic tools and timing to better patient outcomes.
A study using nonlinear modeling shows how diagnostics for ovarian cancer (OC) are impacted by the wait time paradox and recommends improving diagnostic tools and timing to better patient outcomes.
A study using nonlinear modeling...
05/11/2026
Journal of Clinical Pathways
News
How Age, Comorbidities, and Race Influence Cancer Treatment in Older Patients
05/05/2026
Rebecca Amrick
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance,...
05/05/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use